CNO Financial Group, Inc. - Q3 2024 10-Q Summary
Business Context and Reporting Period
CNO Financial Group, Inc. is a holding company for a group of insurance companies focusing on health insurance, annuities, and individual life insurance for middle-income pre-retiree and retired Americans. This report covers the quarterly period ended September 30, 2024.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Total Revenues | $1,129.6 million | $947.5 million | $3,352.3 million | $2,976.3 million |
| Net Income (GAAP) | $9.3 million | $167.3 million | $237.9 million | $240.2 million |
| Net Operating Income (Non-GAAP) | $119.2 million | $101.3 million | $291.3 million | $222.2 million |
| Diluted EPS (GAAP) | $0.09 | $1.46 | $2.18 | $2.08 |
| Diluted EPS (Operating) | $1.11 | $0.88 | $2.67 | $1.92 |
| Total Assets | $37,645.4 million | N/A | N/A | N/A |
| Total Liabilities | $34,957.6 million | N/A | N/A | N/A |
| Shareholders' Equity | $2,687.8 million | N/A | N/A | N/A |
| Net Cash from Operating Activities (YTD) | $436.7 million | $406.2 million | N/A | N/A |
Material Changes vs. Prior Period
- GAAP Net Income Decline: Q3 2024 GAAP net income dropped significantly to $9.3 million from $167.3 million in Q3 2023. This was primarily driven by a $127.1 million non-operating loss due to changes in the fair value of embedded derivative liabilities and market risk benefits (MRBs) related to fixed indexed annuities.
- Operating Income Growth: Excluding non-operating items, Net Operating Income increased 17.7% to $119.2 million in Q3 2024 compared to $101.3 million in Q3 2023. YTD operating income rose 31.1% to $291.3 million.
- Actuarial Review Impact: A comprehensive annual actuarial review performed in Q3 2024 resulted in a net favorable impact of $27.3 million to pre-tax operating earnings, primarily driven by higher mortality assumptions for fixed indexed annuities ($36.2 million favorable) partially offset by higher morbidity assumptions for Medicare supplement products ($9.4 million unfavorable).
- Investment Portfolio: Total investments increased to $28.4 billion from $26.1 billion at year-end 2023. Gross unrealized losses on fixed maturities decreased to $1.8 billion from $2.3 billion at year-end 2023, reflecting improved market conditions.
- Debt Issuance: In May 2024, the company issued $700 million of 6.450% Senior Notes due 2034. Proceeds are expected to be used for general corporate purposes, including the repayment of $500 million in notes due in May 2025.
Guidance, Outlook, and Risks
- Revised Guidance: Management raised full-year 2024 operating earnings per diluted share guidance to $3.50 - $3.60 (previously $3.10 - $3.30). Excess cash flow to the holding company guidance was raised to $250 million - $275 million (previously $140 million - $200 million).
- Expense Ratio: The projected full-year expense ratio is expected to be between 19.0% and 19.2%.
- Capital Targets: The company targets a consolidated Risk-Based Capital (RBC) ratio of 375% for U.S. subsidiaries (actual was 388% at Sept 30, 2024) and a debt-to-total capital ratio (excluding AOCI) of 25% - 28%.
- Risks and Contingencies:
- Market Risk: Significant volatility in earnings is driven by changes in the fair value of embedded derivatives and MRBs, which are sensitive to interest rates and equity market performance.
- Investment Risk: The portfolio contains $1.2 billion in below-investment grade securities. While no defaults were reported, future credit migration could impact capital.
- Regulatory/Litigation: Ongoing litigation includes a case involving Platinum Partners Value Arbitrage Fund regarding reinsurance agreements and a class action regarding optional premium payment provisions. The company does not believe these will have a material adverse effect but notes the inherent unpredictability of legal outcomes.
- Tax Method Change: The company requested IRS approval for a change in tax accounting method for indirect costs allocable to self-constructed real estate assets, which could generate a $985 million tax loss carryforward if approved.
Key Facts for Investor Verification
- Non-GAAP Reconciliation: Verify the reconciliation of GAAP Net Income ($9.3M) to Net Operating Income ($119.2M) to understand the magnitude of non-operating fair value adjustments.
- Actuarial Assumption Changes: Review the specific impacts of the Q3 2024 actuarial review on fixed indexed annuity margins versus Medicare supplement margins.
- Debt Maturity Profile: Confirm the plan to use proceeds from the 2034 Notes to refinance the $500 million 2025 Notes to assess near-term liquidity requirements.
- Investment Credit Quality: Monitor the $1.2 billion below-investment grade portfolio and the $25.9 million allowance for credit losses on fixed maturities.
- Share Repurchases: Note that $190 million was spent on share repurchases YTD 2024, with $331.8 million of authority remaining.